BiotechTube

Intrarectal quinine

Phase 3UNKNOWN
0 views this week 0 watching💤 Quiet
Interest: 36/100
36
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Cerebral Malaria

Conditions

Cerebral Malaria

Trial Timeline

Sep 1, 2003 → Jan 1, 2004

NCT ID
NCT00124267

About Intrarectal quinine

Intrarectal quinine is a phase 3 stage product being developed by Sanofi for Cerebral Malaria. The current trial status is unknown. This product is registered under clinical trial identifier NCT00124267. Target conditions include Cerebral Malaria.

What happened to similar drugs?

5 of 16 similar drugs in Cerebral Malaria were approved

Approved (5) Terminated (1) Active (11)
✅mouse nerve growth factorSun PharmaceuticalApproved
✅RosuvastatinAstraZenecaApproved
✅clopidogrel (SR25990C)SanofiApproved
✅PiracetamUCBApproved
✅Baclofen, Diazepam, Clonazepam, Trihexyphenidyl, Tetrabenazine, Gabapentin, Topiramate, Lamotrigine, Amitriptyline.Brain BiotechApproved
🔄Oral Glycopyrrolate LiquidShionogiPhase 3
🔄NXY-059AstraZenecaPhase 3

Hype Score Breakdown

Clinical
17
Activity
4
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00124267Phase 3UNKNOWN

Competing Products

20 competing products in Cerebral Malaria

See all competitors
ProductCompanyStageHype Score
mouse nerve growth factorSun PharmaceuticalApproved
39
Edaravone Dexborneol + PlaceboSun PharmaceuticalPhase 2
31
Oral Glycopyrrolate LiquidShionogiPhase 3
40
recombinant human erythropoietin alfa + 0.9% NaClJohnson & JohnsonPhase 2/3
38
UDI-001Rohto PharmaceuticalPhase 1/2
32
NXY-059AstraZenecaPhase 3
40
NXY-059AstraZenecaPhase 2
35
RosuvastatinAstraZenecaApproved
39
NXY-059AstraZenecaPhase 3
40
Comparator: Placebo + Comparator: MK0724MerckPhase 2
27
Vorapaxar 2.5 mg + Vorapaxar 1 mg + Placebo + Aspirin 75-150 mgMerckPhase 2
35
Recombinant Factor VIIa + Biological/Vaccine: PlaceboNovo NordiskPhase 3
47
Recombinant Activated Factor VII (rFVIIa) + PlaceboNovo NordiskPhase 3
44
PonezumabPfizerPhase 2
35
PF-05230907PfizerPhase 1
21
Azithromycin + Pyrimethamine + Leucovorin calciumPfizerPhase 1
29
clopidogrel (SR25990C)SanofiApproved
43
PiracetamUCBApproved
35
Placebo + ALN-APPAlnylam PharmaceuticalsPhase 2
39
CN-105Tiantan BioPhase 2
28